Skip to main navigation
Fulcrum Therapeutics logo
Menu Button

Main Menu

  • About
  • Our Approach
  • Pipeline
    • Publications
  • Therapeutic Focus
    • FSHD
    • SCD
    • Beta-thalassemia
  • Careers
    • Current Openings
    • Faces of Fulcrum
  • Investor Relations
    • News Releases
    • Events and Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
  • Contact

News Releases

News Releases

Jun 20, 2023
Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)
Jun 09, 2023
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2023
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
May 15, 2023
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
May 08, 2023
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET
May 05, 2023
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 07, 2023
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 05, 2023
Fulcrum Therapeutics Announces CFO Resignation
Mar 10, 2023
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 09, 2023
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
  • Page 3
  • Next page next ›
  • Last page last »
Displaying 11 - 20 of 29

Investor Tools

Print
Email Page
Email Alerts
IR Contact
Code of Conduct & Business Ethics
Privacy Policy | EU Privacy Policy | Terms of use
Fulcrum TX
Social Media Guidelines

Main Menu

  • About
  • Our Approach
  • Pipeline
    • Publications
  • Therapeutic Focus
    • FSHD
    • SCD
    • Beta-thalassemia
  • Careers
    • Current Openings
    • Faces of Fulcrum
  • Investor Relations
    • News Releases
    • Events and Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
  • Contact